Biological Products, (No Diagnostic Substances) · DE · CIK 1815776
Develops and commercializes VIZZ, an eye drop to improve near vision for presbyopia
Comparable business profile · signals at a glance
In the 90 days to Mar 27, 2026: 3 insiders bought $366K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Schimmelpennink Evert B.President, CEO and Secretary | Buy | 28,089 | $8.95 | $251K |
| Mar 27, 2026 | Chevallard Daniel R.Chief Financial Officer | Buy | 7,500 | $8.57 | $64K |
| Mar 27, 2026 | George Jeffrey P.Director | Buy | 5,592 | $8.92 | $50K |
| Nov 17, 2025 | Olsson ShawnChief Commercial Officer | Sell | 5,788 | $26.37 | $153K |
| Nov 17, 2025 | Olsson ShawnChief Commercial Officer | Sell | 4,212 | $25.74 | $108K |
| Nov 7, 2025 | Mccollum James WDirector | Buy | 10,500 | $22.79 | $239K |
| Nov 7, 2025 | Chevallard Daniel R.Chief Financial Officer | Buy | 2,178 | $22.76 | $50K |
| Nov 7, 2025 | Chevallard Daniel R.Chief Financial Officer | Buy | 20 | $22.71 | $454 |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 83,066 | $46.41 | $3.9M |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 57,502 | $46.41 | $2.7M |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 49,701 | $45.35 | $2.3M |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 34,405 | $45.35 | $1.6M |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 177 | $47.01 | $8K |
| Sep 30, 2025 | Versant Vantage Ii Gp-Gp, LlcTenPercentOwner | Sell | 123 | $47.01 | $6K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.